Literatur
- 1
Bartley G B, Fatourechi V, Kadrmas E F, Jacobsen S J, Ilstrup D M, Garrity J A, Gorman C A.
Chronology of Graves' ophthalmopathy in an incidence cohort.
Am J Ophthalmol.
1996;
121
426-434
- 2 Mourits M P.
Historical notes on Graves' disease. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 246-253
- 3
Wiersinga W M, Smit T, van der Gaag R, Koornneef L.
Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal
Graves' disease.
J Endocrinol Invest.
1988;
11
615-619
- 4
Kendler D L, Lippa J, Rootman J.
The initial clinical characteristics of Graves' orbitopathy vary with age and sex.
Arch Ophthalmol.
1993;
111
197-201
- 5
Bartley G B, Fatourechi V, Kadrmas E F, Jacobsen S J, Ilstrup D M, Garrity J A, Gorman C A.
The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota.
Am J Ophthalmol.
1995;
120
511-517
- 6 Daumerie C, Kalmann R.
Epodemiology. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 34-40
- 7
Eckstein A, Esser J.
Endokrine Orbitopathie. Pathogenese, klinisches Bild und Untersuchung, stadienabhängige
Therapie.
Ophthalmologe.
2003;
100
857-880
- 8 Orgiazzi J.
Pathogenesis. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 41-56
- 9
Saber E, McDonnell J, Zimmermann K M, Yugar J E, Feldon S E.
Extraocular muscle changes in experimental orbital venous stasis: some similarities
to Graves' orbitopathy.
Graefes Arch Clin Exp Ophthalmol.
1996;
234
331-336
- 10
Heufelder A E, Herterich S, Ernst G, Bahn R S, Scriba P C.
Analysis of retroorbital T cell antigen receptor variable region gene usage in patients
with Graves' ophthalmopathy.
Eur J Endocrinol.
1995;
132
266-277
- 11
Baker G, Mazziotti G, von Ruhland C, Ludgate M.
Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy.
Endocrinology.
2005;
146
835-844
- 12
Gerding M N, van der Meer J W, Broenink M, Bakker O, Wiersinga W M, Prummel M F.
Association of thyrotrophin receptor antibodies with the clinical features of Graves'
ophthalmopathy.
Clin Endocrinol (Oxf).
2000;
52
267-271
- 13
Eckstein A K, Finkenrath A, Heiligenhaus A, Renzing-Köhler K, Esser J, Krüger C, Quadbeck B,
Steuhl K P, Gieseler R K.
Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH
receptor suggests involvement of TSHR-specific autoantibodies.
Acta Ophthalmol Scand.
2004;
82
291-297
- 14
McKeag D, Lane C, Lazarus J H, Baldeschi L, Boboridis K, Dickinson A J, Hullo A I,
Kahaly G, Krassas G, Marcocci C, Marinò M, Mourits M P, Nardi M, Neoh C, Orgiazzi J,
Perros P, Pinchera A, Pitz S, Prummel M F, Sartini M S, Wiersinga W M. European Group
on Graves' Orbitopathy (EUGOGO) .
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy
(EUGOGO) survey.
Br J Ophthalmol.
2007;
91
455-458
- 15
Hales I B, Rundle F F.
Ocular changes in Graves' disease. A long-term follow-up study.
Q J Med.
1960;
29
113-126
- 16
Kahaly G, Förster G, Pitz S, Rösler H P, Mann W.
Aktuelle interdisziplinäre Diagnostik und Therapie der endokrinen Orbitopathie.
Dtsch Med Wschr.
1997;
122
27-32
- 17
Kalmann R, Mourits M P.
Late recurrence of unilateral graves orbitopathy on the contralateral side.
Am J Ophthalmol.
2002;
133
727-729
- 18
Eckstein A K, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J,
Morgenthaler N G.
Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy
and help to predict severity and outcome of the disease.
J Clin Endocrinol Metab.
2006;
91
3464-3470
- 19
Mourits M P, Koornneef L, Wiersinga W M, Prummel M F, Berghout A, van der Gaag R.
Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy:
a novel approach.
Br J Ophthalmol.
1989;
73
639-644
- 20
Werner S C.
Modification of the classification of the eye changes in Graves' disease.
Am J Ophthalmol.
1977;
83
725-727
- 21 Pitz S.
Orbital imaging. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 57-65
- 22
Kahaly G, Diaz M, Just M, Beyer J, Lieb W.
Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Thyroid.
1995;
5
107-111
- 23
Durak I, Durak H, Ergin M, Yürekli Y, Kaynak S.
Somatostatin receptors in the orbits.
Clin Nucl Med.
1995;
20
237-242
- 24
Kahaly G, Förster G, Hansen C.
Glycosaminoglycans in thyroid eye disease.
Thyroid.
1998;
8
429-433
- 25
Molnar I, Balazs C.
High circulating IL‐6 levels in Graves' ophthalmopathy.
Autoimmunity.
1997;
25
91-96
- 26
Rootman J.
Why “orbital pseudotumour” is no longer a useful concept.
Br J Ophthalmol.
1998;
82
339-340
- 27 Lazarus J H, Marino M.
Orbit-thyroid relationship. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 27-33
- 28
Kahaly G J, Petrak F, Hardt J, Pitz S, Egle U T.
Psychosocial morbidity of Graves' orbitopathy.
Clin Endocrinol (Oxf).
2005;
63
395-402
- 29
Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A,
Pinchera A.
More on smoking habits and Graves' ophthalmopathy.
J Endocrinol Invest.
1989;
12
733-737
- 30
Bartalena L, Marcocci C, Tanda M L, Manetti L, Dell'Unto E, Bartolomei M P, Nardi M,
Martino E, Pinchera A.
Cigarette smoking and treatment outcomes in Graves' ophthalmopathy.
Ann Intern Med.
1998;
129
632-635
- 31
Holt P G.
Immune and inflammatory function in cigarette smokers.
Thorax.
1987;
42
241-249
- 32
Winsa B, Adami H O, Bergström R, Gamstedt A, Dahlberg P A, Adamson U, Jansson R, Karlsson A.
Stressful life events and Graves' disease.
Lancet.
1991;
338
1475-1479
- 33
Yoshiuchi K, Kumano H, Nomura S, Yoshimura H, Ito K, Kanaji Y, Kuboki T, Suematsu H.
Psychosocial factors influencing the short-term outcome of antithyroid drug therapy
in Graves' disease.
Psychosom Med.
1998;
60
592-596
- 34
Benker G, Kahaly G J, Reinwein D.
What can the European Multicenter Trial on the treatment of Graves' disease with antithyroid
drugs teach us about the course of thyroid-associated orbitopathy (TAO)? European
Multicenter Trial Group.
Exp Clin Endocrinol Diabetes.
1999;
107 (Suppl. 5)
S186-S189
- 35
Tallstedt L, Lundell G.
Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.
Thyroid.
1997;
7
241-245
- 36
Kazim M, Goldberg R A, Smith T J.
Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale
for therapy.
Arch Ophthalmol.
2002;
120
380-386
- 37 Kahaly G J.
Management of moderately severe Graves' orbitopathy. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 120-152
- 38
Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits M P, Wiersinga W M.
Determinants of liver damage associated with intravenous methylprednisolone pulse
therapy in Graves' ophthalmopathy.
Thyroid.
2007;
17
357-362
- 39
Gursoy A, Cesur M, Erdogan M F, Corapcioglu D, Kamel N.
New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a
patient with Graves' ophthalmopathy.
Endocrine.
2006;
29
513-516
- 40
Bartalena L, Marcocci C, Pinchera A.
Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy.
J Clin Endocrinol Metab.
1996;
81
446-448
- 41
Chang C C, Chang T C, Kao S C, Kuo Y F, Chien L F.
Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured
fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema.
Acta Endocrinol (Copenh).
1993;
129
322-327
- 42
Gärtner R, Gasnier B C.
Selenium in the treatment of autoimmune thyroiditis.
Biofactors.
2003;
19
165-170
- 43
Bartalena L, Marcocci C, Tanda M L, Piantanida E, Lai A, Marinò M, Pinchera A.
An update on medical management of Graves' ophthalmopathy.
J Endocrinol Invest.
2005;
28
469-478
- 44
Gärtner R, Gasnier B C, Dietrich J W, Krebs B, Angstwurm M W.
Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid
peroxidase antibodies concentrations.
J Clin Endocrinol Metab.
2002;
87
1687-1691
- 45
Spallholz J E, Boylan L M, Larsen H S.
Advances in understanding selenium's role in the immune system.
Ann N Y Acad Sci.
1990;
587
123-139
- 46
Peretz A, Neve J, Duchateau J, Famaey J P.
Adjuvant treatment of recent onset rheumatoid arthritis by selenium supplementation:
preliminary observations.
Br J Rheumatol.
1992;
31
281-282
- 47
Kahaly G J, Roesler H P, Kutzner J, Pitz S, Müller-Forell W, Beyer J, Mann W.
Radiotherapy for thyroid-associated orbitopathy.
Exp Clin Endocrinol Diabetes.
1999;
107 Suppl. 5
S201-S207
- 48
Kahaly G J, Rösler H P, Pitz S, Hommel G.
Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single
blind trial.
J Clin Endocrinol Metab.
2000;
85
102-108
- 49
Gerling J, Kommerell G, Henne K, Laubenberger J, Schulte-Mönting J, Fells P.
Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison
between 2.4 and 16 Gy.
Int J Radiat Oncol Biol Phys.
2003;
55
182-189
- 50
Mourits M P, van Kempen-Harteveld M L, García M B, Koppeschaar H P, Tick L, Terwee C B.
Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.
Lancet.
2000;
355
1505-1509
- 51
Gorman C A, Garrity J A, Fatourechi V, Bahn R S, Petersen I A, Stafford S L, Earle J D,
Forbes G S, Kline R W, Bergstralh E J, Offord K P, Rademacher D M, Stanley N M, Bartley G B.
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy
for Graves' ophthalmopathy.
Ophthalmology.
2001;
108
1523-1534
- 52 Baldeschi L.
Rehabilitative surgery. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 160-162
- 53 Baldeschi L.
Orbital decompression. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 163-176
- 54
Baldeschi L, Lupetti A, Vu P, Wakelkamp I M, Prummel M F, Wiersinga W M.
Reactivation of Graves' orbitopathy after rehabilitative orbital decompression.
Ophthalmology.
2007;
114
1395-1402
- 55
Sasim I V, de Graaf M E, Berendschot T T, Kalmann R, van Isterdael C, Mourits M P.
Coronal or swinging eyelid decompression for patients with disfiguring proptosis in
Graves' orbitopathy? Comparison of results in one center.
Ophthalmology.
2005;
112
1310-1315
- 56
Trokel S, Kazim M, Moore S.
Orbital fat removal. Decompression for Graves orbitopathy.
Ophthalmology.
1993;
100
674-682
- 57
Adenis J P, Robert P Y, Lasudry J G, Dalloul Z.
Treatment of proptosis with fat removal orbital decompression in Graves' ophthalmopathy.
Eur J Ophthalmol.
1998;
8
246-252
- 58
Kahaly G J, Bumb P, Pitz S, Scheurle C, Ponto K A, Lingl K, Hommel G, Müller-Forell W,
Weber M M, Mann W J.
Operative Entlastung bei endokriner Orbitopathie [Decompression surgery for endocrine
orbitopathy].
Med Klin (Munich).
2007;
102
714-719
- 59
Unal M, Leri F, Konuk O, Hasanreisoğlu B.
Balanced orbital decompression combined with fat removal in Graves ophthalmopathy:
do we really need to remove the third wall?.
Ophthal Plast Reconstr Surg.
2003;
19
112-118
- 60
Baldeschi L, MacAndie K, Hintschich C, Wakelkamp I M, Prummel M F, Wiersinga W M.
The removal of the deep lateral wall in orbital decompression: its contribution to
exophthalmos reduction and influence on consecutive diplopia.
Am J Ophthalmol.
2005;
140
642-647
- 61
Morgenstern K E, Evanchan J, Foster J A, Cahill K V, Burns J A, Holck D E, Perry J D,
Wulc A E.
Botulinum toxin type a for dysthyroid upper eyelid retraction.
Ophthal Plast Reconstr Surg.
2004;
20
181-185
- 62 Nardi M.
Eye muscle surgery. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 176-187
- 63 Neoh C, Eckstein A.
Eyelid surgery. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 188-200
- 64 Wiersinga W M.
Combined thyroid-eye clinics. Wiersinga WM, Kahaly GJ, Hrsg. Graves' orbitopathy – a multidisciplinary approach. Basel;
Karger 2007: 96-99
PD Dr. med. S. Pitz
Universitäts-Augenklinik Mainz
Langenbeckstraße 1
55131 Mainz
eMail: pitz@augen.klinik.uni-mainz.de
